Integrative biology techniques combing human transcriptome profiles with clinically relevant in vivo models have identified IL-22-targeting as a prospective intervention in psoriasis (242) Guselkumab (anti-IL-23) acted as a long-time effector by suppressing IL-17 and IL-22 after withdrawal in the treatment of psoriasis, indicating that IL-22 blockers might be effective in both active and maintenance phases (231). This evidence concerns the gene IL22 and psoriasis.